Updated:
Pharmakon Advisors
Pharmakon Advisors, LP is an investment manager that provides strategic financing to life sciences companies.
Pharmakon Advisors
Pharmakon Advisors, LP is an investment manager that provides strategic financing to life sciences companies. It oversees the BioPharma Credit Investment funds, which have committed over $11 billion across 74 transactions (per firm website). The firm is headquartered in New York. The firm focuses on senior secured loans, royalty-based financings, and other debt structures. Investments span biotechnology, pharmaceuticals, medical technology, and diagnostics. Pharmakon targets late-stage companies with approved products or near-commercial assets. Known deals include financing for clinical-stage biotechs and diagnostic firms. The team size and named professionals are not disclosed on the firm's public website. The firm has committed $11 billion since inception but does not report current AUM. It maintains one office in New York City. Pharmakon operates as a dedicated life sciences credit specialist — distinct from generalist healthcare funds. Its BioPharma Credit funds are structured as closed-end vehicles, providing long-dated capital. This focus on structured debt in a high-risk sector sets it apart from private equity or venture investors.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
110 East 59th Street #2800, New York, NY 10022, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Pharmakon Advisors?
Pharmakon Advisors does not publicly disclose the names of its investment committee or portfolio managers. The firm's website lists no individual principals. Institutional allocators conducting due diligence should request team bios directly.
Is Pharmakon Advisors a family office or an asset manager?
Pharmakon Advisors describes itself as an investment management firm, not a family office. It manages the BioPharma Credit Investment funds, which are investment vehicles open to institutional investors. Its structure is that of a dedicated credit fund manager.
Does Pharmakon Advisors make equity investments or only debt?
Pharmakon focuses on strategic financing solutions, which typically include senior secured loans, royalty-based financings, and other debt structures. It does not publicly report equity investments. Its BioPharma Credit funds are credit vehicles.
What types of life sciences companies does Pharmakon target?
The firm invests across biotechnology, pharmaceuticals, medical technology, and diagnostics. It targets late-stage companies with approved products or near-commercial assets. This positions its loans as lower-risk within the biotech sector.
How large is Pharmakon's total deployment?
As of the firm's website, Pharmakon Advisors has committed over $11 billion across 74 transactions. This figure represents total capital committed, not AUM. Current AUM is not disclosed.
What is the BioPharma Credit Investment fund?
The BioPharma Credit Investment funds are the investment vehicles managed by Pharmakon Advisors. These funds provide structured debt financing to life sciences companies. They are structured as closed-end funds, offering long-dated capital.
Which sectors does Pharmakon explicitly avoid?
Pharmakon does not publicly state sectors it avoids. Based on its disclosed focus, it does not invest in early-stage biotech without products, nor in healthcare services or providers. Its mandate is limited to life sciences companies with commercial or near-commercial assets.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: